Ventric Health has launched a redesigned website aimed at improving access to clinical, operational and implementation information for earlier heart failure detection.
The update centres on the company’s Vivio System, an FDA-cleared non-invasive device for measuring elevated left ventricular end-diastolic pressure, or LVEDP, in an outpatient setting. The redesigned site is intended for primary care physicians, cardiologists, Medicare accountable care organisations and health systems seeking to address delays in heart failure diagnosis.
Heart failure remains difficult to identify early, particularly in patients whose symptoms may be non-specific or gradually progressive. According to Ventric Health, approximately 65 per cent of at-risk patients receive their first diagnosis in an emergency room or inpatient setting, an average of 30 months after symptom onset. This delay can increase the clinical and economic burden of care.
The cost difference is also notable. The company said late-stage management costs $21,800 per patient annually, compared with $4,300 when heart failure is identified earlier. This provides a clear operational rationale for shifting diagnosis into outpatient and primary care environments, where patients may be assessed before disease progression leads to acute care utilisation.
The redesigned website includes an expanded resources hub with peer-reviewed research, workflow guidance and role-specific content tracks for clinical and administrative leaders. It also provides a stage-by-stage breakdown of heart failure progression and more detailed information on Vivio’s real-world implementation.
From a workflow perspective, the update reflects the importance of aligning diagnostic technology with practical adoption pathways. Health systems evaluating outpatient heart failure detection tools often require more than product information; they need evidence summaries, implementation models, clinical use cases and clarity on how the technology fits into existing care pathways.
Vivio measures LVEDP non-invasively using a physics-based analysis of cardiac pressure and volume waveforms. The point-of-care test is completed in under five minutes and does not require imaging, referral or invasive procedures. The system also pairs physiologic data with the Kansas City Cardiomyopathy Questionnaire-12 to provide a broader clinical view of the patient.
The company highlighted published evidence supporting Vivio, including a 2025 multicentre JAHA validation study, a 2025 HFSA abstract on pre-symptomatic Stage A detection and a JACC Advances study on primary care screening. The system is currently available only in the United States.
The website launch is not a product approval milestone, but it is commercially relevant. For digital and device-enabled diagnostics, adoption depends heavily on clinician education, payer alignment, operational clarity and ease of evaluation. By consolidating clinical evidence and access pathways, Ventric Health is positioning the Vivio System for broader engagement with outpatient providers and health systems focused on earlier heart failure intervention.
